Cinnarizine As an Alternative Recommendation for Migraine Prophylaxis: A Narrative Review Publisher Pubmed



Togha M^{1, 2} ; Martami F¹ ; Abdollahi M¹ ; Mozafari M¹ ; Cheraghali H³ ; Rafiee P⁴ ; Shafaei M¹ Show Affiliations
Source: Expert Review of Neurotherapeutics Published:2020

Abstract

Introduction: Despite the available prophylactic and acute drugs for migraine management, this disabling disorder remains undertreated especially among pediatrics. In this review, the authors aim at assessing the preventive role cinnarizine plays in treating migraine based on previously published studies. Areas covered: Randomized clinical trials, randomized controlled trials, non-randomized open-label trials, and retrospective studies concerning cinnarizine in migraine prevention in children and adults were reviewed. Especial attention was given to the response rate, migraine characteristics, and tolerability. Expert opinion: The majority of reviewed trials demonstrated that cinnarizine is comparable to the conventional drugs used in migraine prophylaxis. However, most of the reviewed studies were limited by a non-controlled open-label design. Due to poor planning and possibility of high placebo responses, particularly in children and adolescents, the interpretation of open-label studies’ results should be done cautiously. The evidence shows that cinnarizine’s effectiveness was more promising in pediatric migraineurs and adults with migraine-associated vertigo such as vestibular migraine. Therefore, while the efficacy of cinnarizine cannot be dismissed, before reaching a definite conclusion on its effectiveness, it is necessary to do further high-quality RCTs among both children and adults. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.